Abstract
Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have